Once confined to the margins of lifestyle care, anti-obesity drugs have now emerged as one of the world’s fastest-growing pharmaceutical segments. According to McKinsey, this category ranks alongside artificial intelligence, electric vehicles, and robotics as a potential trillion-dollar opportunity by 2040. In India, the rapid expansion of weight-loss and metabolic therapies is set to define the pharma growth narrative in 2026, especially as affordable generics enter the market.
India’s Obesity and Metabolic Therapy Market Gains Momentum
With lifestyle diseases rising sharply, India is witnessing a surge in demand for obesity and diabetes therapies. Nearly 100 million adults live with diabetes, while obesity-linked conditions continue to increase. As a result, India’s anti-obesity market—valued at just over ₹1,000 crore (MAT November)—has expanded nearly ten-fold in five years.
Blockbuster Launches Signal Strong Demand
Global pharmaceutical leaders have responded swiftly to this growing demand. Blockbuster therapies such as Wegovy and Mounjaro, marketed by Novo Nordisk and Eli Lilly respectively, launched earlier this year at India-specific prices. Additionally, the global bestseller Ozempic has recently entered the Indian market, further intensifying competition and awareness.
Industry Leaders Emphasise Patient-Centric Solutions
Highlighting the shift towards holistic care, Kirti Ganorkar, Managing Director, Sun Pharma, said that rising lifestyle diseases demand patient-centric solutions. He noted that broader access to GLP-1 medicines for obesity and diabetes could significantly reduce the long-term burden of these conditions.
Echoing this view, Winselow Tucker, President and GM, Eli Lilly & Co (India), said India is entering a transformative phase in obesity and chronic weight-management care. He attributed this shift to increased disease recognition, growing patient awareness, and wider access to evidence-based prescription therapies.
A Largely Untapped Market with Significant Headroom
Despite rapid growth, experts believe the market remains under-penetrated. Sheetal Sapale, Vice-President (Commercial), Pharmarack, pointed out that India’s obesity market still offers substantial headroom for both innovators and generic manufacturers, creating long-term growth opportunities.
Generics Set to Accelerate Market Expansion
As reported by TOI, from March 2026, the entry of low-priced generics is expected to further fuel market growth as semaglutide, the key ingredient in blockbuster weight-loss injections, loses patent protection. Moreover, potential price reductions by innovator companies could significantly improve affordability and access, accelerating adoption across income segments.
Focus Shifts to Lifestyle Disease Management
According to Bhanu Prakash Kalmath SJ, Healthcare Industry Leader at Grant Thornton Bharat, the industry is clearly pivoting toward GLP-1 therapies, digital health tools, and preventive lifestyle programmes. In the near term, he expects deeper partnerships between pharma companies, consumer health players, and digital platforms to expand access beyond major urban centres.
AI Transforms Drug Discovery and R&D
In parallel, pharmaceutical companies are rapidly increasing AI-led investments across the value chain. AI adoption in drug discovery is shortening development timelines, improving R&D productivity, and enhancing commercial outcomes. Consequently, many firms are shifting from simple generics to niche and complex formulations.
Biocon Highlights Convergence of AI and Advanced Therapies
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, noted that the convergence of AI, digital technologies, and personalised medicine will accelerate innovation. She added that India’s growing ecosystem for affordable cell and gene therapies, along with biosimilars and complex biologics, is strengthening the country’s position as a global innovation hub. Additionally, the rapid growth of CRDMOs is positioning India as a preferred destination for high-value pharmaceutical outsourcing.
Domestic Pharma Gears Up for 2026
Looking ahead, Indian pharmaceutical companies are scaling up R&D in advanced biologics, GLP-1 therapies, antibody-drug conjugates, and cell and gene therapies. Srikanth Mahadevan, Director, Deloitte India, observed that companies are increasingly pivoting from volume-driven generics to high-complexity products.
Private Equity and Market Diversification Gain Importance
At the same time, private equity interest remains strong across hospitals, medical services, and digital health platforms. Sujay Shetty, Global Health Industries Advisory Leader, PwC India, added that pharma companies are also actively diversifying into non-US markets to reduce dependence on the US generics business and mitigate risk.
A Defining Phase for Indian Pharma
Together, the rise of obesity drugs, expansion of AI-driven innovation, entry of generics, and strategic diversification are reshaping India’s pharmaceutical landscape. As the sector moves toward 2026, these trends are expected to position India as a key driver of global growth in metabolic care and advanced therapeutics.